Vortex “As a clinician, I am excited about accessing the cancer biology of patient’s through CTCs. Vortex’s technology provides the best source of CTCs to aid in the diagnostic and treatment decisions we face every day.” – Dr. Jonathan Goldman, MD, Director of Clinical Trials in Thoracic Oncology, Associate Director of Drug Development at UCLA “Improving CTCs recovery along with high cellular purity while maintaining viability have tremendous value for translational research and clinical diagnostic applications. The VTX-1 holds the potential to revolutionize blood-based diagnostics.” - Pr. Massimo Cristofanilli, MD, FACP, Professor of Medicine, Associate Director of Translational Research and Precision Medicine, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine Wanda J. Cribbs, Lead Gartner Analyst Population Health & Analytics says: "Wanda's recent HRS press release really stands out. Delivering those results and having a client publicly share credit with their vendor is rare and says a lot. We at Gartner will have our eyes on Wanda in 2018"

Professor Stephen Smith

Non-Executive Director

Professor Stephen Smith, Non-Executive Director, joined the NetScientific Board in 2016.

Stephen has held senior leadership roles in the NHS and academia. He has had a long and distinguished career as a clinician scientist, Head of Department, Dean and CEO.
His name is associated with the Medical Research Council, University of Cambridge, Imperial College, London and Imperial College Healthcare NHS Trust.

He was responsible for the largest merger in the NHS, the creation of the UK’s first Academic Health Science Centre in 2007. The merger brought together four London based NHS Trusts and ultimately led to the creation of Imperial College Healthcare NHS Trust, where Stephen served for four years as the first CEO. He also retained his position as Dean of the Faculty of Medicine at Imperial College, London and was responsible for facilitating the commercialisation of life sciences and healthcare.

During his career, Stephen has spun two companies out of Cambridge – Metris Therapeutics Ltd and GNI Group Ltd. GNI was established as a start up in Japan in 2001 and successfully achieved an Initial Public Offering (IPO) on the Tokyo Stock Exchange six years later.

Stephen has extensive non-executive experience serving on the Boards of the National Healthcare Group Singapore which developed integrated care through nine polyclinics. In Australia, he was on the Board of the Royal Melbourne Hospital and the Victorian Comprehensive Cancer Centre, a $1billion project to create a fully integrated cancer care facility that brings together an integrated research, service and education offering to four million patients in Victoria.

Professor Stephen Smith - NetScientific
No announcement available or all announcement expired.